Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock
"The thrill of victory and the agony of defeat."
That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR Therapeutics (NASDAQ: CRSP) and (NYSE: PFE) in 2023. CRISPR Therapeutics has enjoyed the thrill of victory, while Pfizer has experienced the agony of defeat.
But which of these two biopharmaceutical stocks is the better pick for a new bull market? Motley Fool contributors Adria Cimino and Keith Speights make the arguments for CRISPR Therapeutics and Pfizer, respectively.
Source Fool.com
Pfizer Inc. Stock
The stock is one of the favorites of our community with 30 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 59.1% compared to the current price of 25.77 € for Pfizer Inc..